In the media
CeiROx Life Sciences Wins Most Innovative in Regenerative Medicine – Switzerland
Winners in the Corporate LiveWire Innovation & Excellence Awards 2020
CeiROx Life Sciences – currently functioning as BioTissue – is a group that operates in the field of biotechnology, offering state-of-the-art regenerative medicine solutions. The group has developed a technology platform that has given birth to therapies aiming at tissue regeneration across different applications, with the goal of providing pertinent and sustainable solutions to a population with a higher life expectancy. Their core operations are between Switzerland and Germany, and they currently serve European and Asian markets with future plans for North and Latin America.
CeiROx’s product development strategy is to provide and improve solutions through user-friendly answers from medical, regulatory and business perspectives. This was displayed by the group in the development of their fourth-generation tissue engineering product, which overcame key drawbacks such as complex procedures and cost-intensive cell culture and clinical treatment. CeiROx are in a transformational moment; transitioning from a lab-focused company to a market-oriented one and enacting their business proposition around an economic model to serve the world’s patients and healthcare professionals.As they continue to grow, the group prioritise the health and recovery of full and empowering capacities for patients; public health being improved from a government standpoint, with an abler population reducing disability in the overall population; the cost to the healthcare system being continuously minimised; the user-friendliness of application to the healthcare professional; and profitability and return, providing the basis for a sustainable enterprise and shareholder’s value.
The judges commend CeiROx for their aptitude to secure the highest possible outcome for sustainable impact on the patient’s health, and on the company’s business model. Capitalising on their accumulated biotechnology knowledge, the group have impressively introduced new growth strategies that offer solutions to the drawbacks of the previous stage of development. As CeiROx take their first steps into the market, they have demonstrated an outstanding capacity to provide vital scaling opportunities. Judge Andrew Walsh commented: “CeiROx are delivering important, groundbreaking biotechnology solutions to those who need them most, with a vision of changing lives.”
Comments